US Patent 12,594,268: What Claims Cover for Migalastat Treatment of Fabry Disease and How the Patent Estate Shapes US Generic/Branded Competition
US Patent 12,594,268 (US 12,594,268) claims treatment methods for Fabry disease using migalastat (or a salt) in patients whose alpha-galactosidase A (GLA) mutations are limited to a defined subset. Independent claim 1 covers “method for treatment” dosing without requiring a particular salt form, but it tightly requires patient genotype. Dependent claims narrow further to dosing frequency (every other day), dose range (100 to 150 mg free base equivalent), a specific salt strength (150 mg migalastat hydrochloride every other day), patient sex, and where the mutation is disclosed (a pharmacological reference table, including within an approved migalastat product label). Claim 9 locks in D33H as a further genotype-specific sub-scope.
This genotype-constrained structure is typical of “population selection” strategy patents: they limit infringement to patients with specified mutations and to therapeutic administration. The practical enforcement and litigation posture for competitors typically turns on (1) whether the accused label or promotional material induces treatment of those mutation subsets, (2) whether the accused dosing matches the claimed schedules and amounts, and (3) whether patient-specific genotype selection arguments align with FDA label wording and available companion diagnostic or genotype testing workflows.
What is US Patent 12,594,268 and what is the claimed invention scope for migalastat + specific GLA mutations?
US 12,594,268 is a US-method patent that claims therapeutic methods for Fabry disease by administering migalastat (free base or salts) to human patients meeting a genotype requirement: an alpha-galactosidase A mutation selected from eight enumerated mutations.
Claim 1 (independent): the core scope
Claim 1 requires all of the following elements:
- Act: “administering to the patient a therapeutically effective dose of migalastat or a salt thereof”
- Indication: Fabry disease treatment
- Patient eligibility: the patient has an α-galactosidase A mutation selected from:
- D33H
- G35A
- Y88S
- T194A
- W204G
- Y216S
- Q250K
- R392T
Practical read-through: Claim 1 is not a formulation claim, not a manufacturing claim, and not limited to a particular salt form or exact mg amount other than “therapeutically effective dose.” It is limited by patient genotype.
Dependent claims: narrowing dimensions
- Claim 2: dosing frequency is every other day
- Claim 3: dose is 100 to 150 mg free base equivalent every other day
- Claim 4: specific dosing embodiment is 150 mg migalastat hydrochloride every other day
- Claims 5 and 6: patient is male or female (sex is included but does not expand beyond claim 1; it narrows to specific patient demographics)
- Claim 7: the mutation is disclosed in a “pharmacological reference table”
- Claim 8: the pharmacological reference table is provided in a product label for an approved migalastat product
- Claim 9: mutation is D33H (subset of claim 1)
How do the migalastat Fabry genotype requirements in US 12,594,268 affect infringement risk and claim coverage?
Genotype limitation is the primary infringement gate
For method claims, the genotype element typically functions as the strictest boundary:
- If an accused regimen treats Fabry patients outside the eight mutation set, claim 1 is not satisfied.
- If a regimen treats one of the eight mutations, claim 1 is satisfied only if the regimen also includes administration of migalastat (or a salt) in a therapeutically effective dose.
This creates a “slice” patent: it targets a defined responsive genotype subset rather than all Fabry disease patients.
“Therapeutically effective dose” vs. explicit dose claims
Claim 1’s “therapeutically effective dose” is broad. That broadness is tempered by the dependent claims that specify:
- every-other-day dosing (claim 2),
- a mg range (claim 3),
- a specific salt and dose (claim 4).
In practice:
- Competitors using different frequency or different amounts can be harder to map to the narrower dependent claims.
- Claim 1 can still be asserted in a more fact-intensive way where dosing arguably is “therapeutically effective,” even if not matching claims 2-4 exactly.
Mutation disclosure pathway (table in label) narrows evidentiary paths
Claims 7 and 8 introduce an additional framing:
- the mutation “is disclosed in a pharmacological reference table”
- and in claim 8 that table is located in an approved migalastat product label.
This may matter in:
- claim construction disputes about what counts as “pharmacological reference table,”
- evidentiary use in infringement (for example, using label text to establish that a particular mutation belongs to the table).
What do claims 2–4 cover for migalastat dosing (every other day; 100–150 mg free base equivalent; 150 mg migalastat hydrochloride)?
Claim chart style mapping (high-level)
| Limitation |
Where it appears |
Scope effect |
| Every-other-day administration |
Claim 2 |
Narrows to schedule |
| 100–150 mg free base equivalent every other day |
Claim 3 |
Narrows to dose range |
| 150 mg migalastat hydrochloride every other day |
Claim 4 |
Narrows further to a specific salt form and dose |
Implications for design-around
A competitor seeking to avoid dependent-claim overlap might consider:
- alternate dosing schedules that deviate from every other day,
- dose levels outside 100–150 mg free base equivalent,
- alternative salt forms or strengths that do not match the “150 mg hydrochloride” embodiment.
However, such changes may still fall under claim 1 if the administration is “therapeutically effective,” meaning claim 1 remains the persistent baseline risk when the genotype is one of the eight enumerated mutations.
Which GLA mutations are explicitly listed in US 12,594,268 and how do they structure the patent’s population coverage?
Enumerated mutation set
US 12,594,268 limits claim 1 to:
- D33H
- G35A
- Y88S
- T194A
- W204G
- Y216S
- Q250K
- R392T
Single-mutation dependent fallback
- Claim 9 specifies D33H, making it a clear additional hook for genotype-specific enforcement.
Population coverage logic
From a business and litigation standpoint:
- enforcement is aimed at patients whose GLA variants are in the enumerated set,
- genotype testing and mapping to label or reference tables can be central to infringement proof.
What is the role of sex limitations (male vs female) in claim scope and enforceability?
- Claim 5: male patients
- Claim 6: female patients
These are not typical “therapeutic effect” differentiators since Fabry disease treatment is generally applicable across sexes. Here, the sex limitations function as additional narrowing elements. In infringement analysis, sex restrictions can reduce the population further if an accused regimen involves only one sex or if clinical evidence is sex-stratified.
How do claims 7 and 8 interact with FDA labeling and “pharmacological reference tables”?
Claim 7: mutation must be disclosed in a pharmacological reference table
This suggests the patent ties the mutation list to a recognized reference format (table). The claim language requires that the mutation “is disclosed” in that table.
Claim 8: table is in a product label for an approved migalastat product
This ties the claim to label content. In disputes, accused parties may argue:
- that a different labeling format or updated label does not contain the same “pharmacological reference table” wording,
- that the relevant table differs from what the patent envisions.
From the patentee’s angle, the label anchor can be used to:
- identify whether each enumerated mutation appears in the label’s responsive genotype listing,
- support an inference that physicians and patients are guided toward the exact genotype selection claimed.
What patents likely overlap with US 12,594,268 in the migalastat Fabry landscape (method-of-use, dosing, and genotype selection)?
Only the claim text you provided is available in this prompt. A complete US patent landscape mapping requires bibliographic data (publication numbers, assignee, priority, family members, expiration dates, continuations, and Orange Book listing details). Without those specifics in the prompt, a comprehensive overlap analysis cannot be produced accurately.
No full patent estate can be enumerated here.
When does US 12,594,268 lose exclusivity and what launch timing risks exist for generics/biosimilars?
No patent expiration date, priority date, or patent term adjustment/extension data is provided in the prompt. Without those, a precise exclusivity timeline cannot be generated.
What is the Orange Book status of US 12,594,268 and what does that mean for Paragraph IV and 505(b)(2) pathways?
The prompt does not include:
- the drug product name(s) associated with US 12,594,268 in the Orange Book,
- listed patents, expiration dates, or dosage forms,
- whether the patent is listed as covering a particular product and strength.
A correct Orange Book status analysis cannot be produced from the information given.
How strong is the patent estate for genotype-constrained migalastat methods, and where are the claim vulnerabilities?
Strength vectors
- Hard limitation via enumerated mutations: Claim 1’s genotype list makes the claim more definite than generic “treat Fabry with migalastat” claims.
- Label-referenced table (claims 7–8): If the approved label contains the mutations in a table, proving infringement may be cleaner.
- Dosing-specific dependent claims: Every-other-day and 150 mg hydrochloride embodiments create targeted infringement hooks.
Primary vulnerability vectors
- Genotype proof: Method-of-use infringement may hinge on patient genotype identification. If accused populations are not within the eight-mutation set, claims 1 and 9 fail on a key element.
- Dosing deviations: Dependent claims 2–4 can be avoided by schedule or dose differences, though claim 1 still carries a “therapeutically effective dose” breadth.
- Interpretation of “pharmacological reference table”: Claim 7/8 can be disputed if label presentation or update history changes what qualifies as the “table.”
Key Takeaways
- US 12,594,268 is a Fabry disease method-of-treatment patent covering administration of migalastat (or salts) only for patients with GLA mutations limited to D33H, G35A, Y88S, T194A, W204G, Y216S, Q250K, and R392T.
- Claim 1 is the broadest hook via “therapeutically effective dose,” with genotype as the central gate.
- Claims 2–4 narrow to every other day dosing, 100–150 mg free base equivalent, and specifically 150 mg migalastat hydrochloride.
- Claims 7–8 tie mutation disclosure to a pharmacological reference table, specifically one included in an approved migalastat product label, strengthening label-based evidentiary alignment.
- Claim 9 provides a single-mutation enforcement path for D33H.
FAQs
- Does US 12,594,268 cover migalastat for all Fabry disease patients or only those with specified GLA mutations?
- If a competitor uses a different dosing schedule than every other day, which claims in US 12,594,268 remain relevant?
- How does the “pharmacological reference table” limitation in claims 7–8 affect infringement proof using FDA label text?
- What additional infringement leverage does claim 9 (D33H) provide compared with claim 1?
- How do sex-specific limitations in claims 5–6 change the covered patient population for method claims?
References (APA)
- US Patent 12,594,268 (claims provided in prompt).
